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ABSTRACT (255 words) 73 
Background. In asthma, short- and long-acting β-agonists (SABAs and LABAs) should be used together 74 
with inhaled corticosteroids (ICS), and regular use is inappropriate.  75 
 76 
Objective. To assess the relationship between patterns of use of therapy and asthma exacerbations 77 
(AEx).  78 
 79 
Methods. Asthmatic patients (6-40 years) were enrolled in France and the United Kingdom. Prescribing 80 
data, Computer-Assisted Telephone Interviews (CATIs), and text messages assessed medication use and 81 
AEx over a maximum period of 24 months. Generalized linear mixed models provided AEx risks 82 
associated with therapy. 83 
 84 
Results. Among the 908 patients (median age: 20.0 years, 46.6% women, 24.5% children) answering a 85 
total of 4,248 CATIs over 486 (±235) days, regular (i.e. daily) use was more frequent for single LABAs 86 
and Fixed Dose Combinations (FDCs) than for single ICS (75.6%, 70.1%, and 65.4% of investigated 87 
periods of use, respectively). Regular (i.e. daily or almost daily) SABA use was observed for 21.1% of 88 
periods of use. Altogether, 265 patients (29.2%) experienced ≥1 AEx. ORs for AEx risk related to 89 
regular vs. no use of FDCs, single ICS, and single LABAs were 0.98 (95% CI=[0.73-1.33]), 0.90 (95% 90 
CI=[0.61-1.33]), and 1.29 (95% CI=[0.76-2.17]), respectively, after  adjustment for cotherapy, socio-91 
demographic, and disease characteristics. The OR was 2.09 (95% CI=[1.36-3.21]) in regular SABA 92 
users. 93 
 94 
Conclusion. ICS and FDCs were often used intermittently whereas SABAs and LABAs could be used 95 
regularly, and exacerbations were frequent. Compared to non-users, the risk of exacerbation increased 96 
moderately under regular use of single LABAs, while it doubled, significantly, in regular SABA users, 97 








The safety of long-acting β-agonists (LABAs) remains controversial in patients with asthma, prompting 102 
regulators to contraindicate LABAs for use as single agents to treat asthma 1. GINA guidelines also 103 
emphasize the need to avoid a regular use of short-acting β-agonists (SABAs) without concurrent ICS 104 
use, a situation frequently observed in routine care, where overreliance on SABAs and poor adherence 105 
to ICS are common 2, 3. Recent clinical trials have compared LABAs in fixed dose combinations (FDCs) 106 
with ICS, obtaining reassuring findings regarding the occurrence of nonlethal exacerbations 4-8. 107 
Evidence is nonetheless limited in the context of routine clinical care, where inappropriate use of therapy 108 
may impact safety and effectiveness 9. A systematic review assessing the risks associated with LABAs 109 
in combination with ICS compared to ICS alone could not reach robust conclusions 10. 110 
 111 
To investigate the effect of LABAs on asthma outcomes under real-life conditions, the European 112 
Medicines Agency requested an observational study collecting prospective information on actual 113 
medication use and ensuing outcomes. Therefore, a study employing a longitudinal design with repeated 114 
assessments of asthma therapy use and exacerbations over time was considered appropriate to examine 115 
LABA safety in real life, based on the assumption that potential risks of would vary between periods of 116 
regular use and periods without use, and according to co-therapy with ICS. In a context of increased 117 
awareness regarding inappropriate use of SABAs in routine care and the potential impact on outcomes, 118 
the study simultaneously collected data on the use of SABAs, allowing assessments of both short- and 119 
long-acting bronchodilators 9. 120 
 121 
 122 







Study design and study population 126 
The methods of the study have been described 11. Briefly, this was a prospective, field study of a cohort 127 
of patients with persistent asthma recruited and followed from 2013 to 2015. The study population 128 
included patients with asthma aged 6-40 years who were recruited in primary care in France and the 129 
United-Kingdom (UK). In the UK, the study identified patients from THIN, a network of Electronic 130 
Health Records (EHRs), whereas in France patients were directly identified by General Practitioners in 131 
their practices. 132 
 133 
Data collection  134 
Trained interviewers administered computer-assisted telephone interviews (CATIs) to patients aged 12-135 
40 years and to parents/caregivers of patients aged 6-11 years immediately after inclusion, and then 136 
every four months during a maximum follow-up period of 24 months. CATIs assessed the type of asthma 137 
medications prescribed at the time of interviews, and patient-reported use and occurrence and type of 138 
asthma exacerbations (AEx) during the last 4 months 12. Patients also received monthly text messages 139 
inquiring whether they had experienced a new AEx since the last study contact. A positive answer 140 
triggered an additional CATI with questions on medication use prior to AEx to ensure that data were 141 
collected as close to the AEx as possible. Socio-demographic data (gender, age, and country of 142 
residence) were obtained from medical records. 143 
 144 
Measures 145 
Outcome  146 
Asthma exacerbation (AEx) was defined as a new OCS course for asthma (≥3 days), an unscheduled 147 
medical contact for asthma, a hospital contact (emergency room visit and/or overnight hospitalization) 148 





CATI, including the type of event. The date of AEx was recorded, and multiple AEx events within 15 150 
days were considered a single event.  151 
 152 
Reported medication use 153 
Medication use was assessed at each CATI, separately for each inhaler reported used in the period 154 
assessed. The questions had been validated before starting patients’ inclusions: they assessed distinct 155 
patterns of use for specific time periods12. LABA use was assessed separately for single LABA inhalers, 156 
regardless of whether they were administered monotherapy or with ICS, and for FDC inhalers. The 157 
assessment was based on a question inquiring about the number of days of LABA or ICS use during the 158 
7 days preceding CATIs, and when an AEx was reported, the 7 days before the occurrence of the AEx; 159 
answers were grouped in 3 categories (none: 0 days of use; irregular use: 1-6 days of use; and regular 160 
use: 7 days of use). The use of short-acting β-agonists (SABAs) in the last four weeks was measured 161 
based on CATI questions inquiring about the frequency of SABA use; responses were grouped into 162 
‘irregular use’ (once or twice weekly or less than once a week) and ‘regular use’ (daily or almost every 163 
day). No prescribed SABAs was considered as ‘no use’.  164 
 165 
Severity markers  166 
For all patients, the 12 months before inclusion -the “pre-study period”- was used to verify inclusion 167 
criteria –e.g., repeated prescribing of controller therapy- and to assess the severity of asthma 11. The 168 
number of OCS courses prescribed during this pre-study period was obtained from medical records.  169 
The daily doses of ICS reported at the first CATI were computed from patient-reported information on 170 
the type of ICS prescribed and daily dosage, and were reported as the beclomethasone equivalent dose 171 
according to GINA equivalence computations 13; values were grouped into 3 categories according to µg 172 
of the beclomethasone equivalent doses in teenagers  and adults (12+) and children (6-11): high (> 173 
1,000 µg and >400 µg, respectively), medium (500-1,000 µg and 200-400 µg, respectively), and low: 174 





The use of leukotriene receptor antagonists (LTRAs) at inclusion was assessed from prescribing data at 176 
the first CATI, coded as a binary variable (yes/no).  177 
 178 
Data analyses 179 
Descriptive analyses  180 
Analyses were based on all available CATI reports; reports contained complete data due to mandatory 181 
completion rules in the CATI online forms. First, patients’ baseline characteristics were summarized as 182 
counts and percentages. Next, patient-reported medication uses were described: the purpose was to 183 
identify inappropriate use, ie “irregular” use among FDC and ICS users, and “regular” use among 184 
users of LABA in single inhalers, and SABA users. Finally, the frequency of asthma exacerbations 185 
(AEx) during follow-up was presented, including the type of AEx.  186 
 187 
Risk of asthma exacerbation (AEx) during medication use  188 
For each medication, we investigated whether the reported use was associated with an AEx occurrence. 189 
A multilevel logistic regression approach was used (Generalized Linear Mixed Models with CATI 190 
reports nested within patients, and a variance component structure to account for correlations among 191 
time points), in which a patient’s use was allowed to change over time. Treatment variables (FDCs, ICS, 192 
single LABAs, SABAs) were entered in the model to detect a potential impact on AEx; ‘0 days’ of use 193 
or absent prescription was considered the reference group. For all medications, a “regular use” was 194 
assumed to maximize the probability of observing a potential impact -positive or negative- on 195 
exacerbations. The model was adjusted for age, gender, country, and markers of severity (dose of ICS 196 
prescribed at inclusion, annual number of episodes of use of OCS before inclusion, prescribed LTRA at 197 
inclusion). 198 






Baseline sample characteristics 201 
The analyses included data from 908 patients who completed at least one CATI (Figure 1). The median 202 
age of the participants was 20.0 years; 46.6% were female, and 55.8%, 19.7% and 24.5% were adults, 203 
teenagers and children, respectively. At inclusion, 28.9% of patients were prescribed ICS without 204 
LABAs, 59.0% were prescribed LABA/ICS FDCs, 9.1% were prescribed LABAs and ICS in distinct 205 
inhalers, and 3.0% (n=27) were prescribed LABAs without ICS. In parallel, 84.7% of patients were 206 
using SABAs at inclusion. At the initial CATI, LTRAs were used by 198 (21.8%) patients, and 710 207 
patients (78.2%) were prescribed low or medium doses of ICS. The average number of OCS courses 208 
during the 12 months before inclusion was 0.45 (±0.90) (Table 1). Missing data only concerned markers 209 
of baseline severity (OCS, and ICS daily doses: 3.2% and 2.6% missing values, respectively), which 210 
were replaced with the most frequent values. 211 
FIGURE 1 212 
TABLE 1 213 
 214 
Medication use during follow-up 215 
Participants were followed for 486 (±235) days. Four thousand two hundred fourty-eight CATIs were 216 
conducted (4,120 regular CATIs and 128 CATIs performed after AEx detection). The global answer 217 
rate to text messages was 66.5%, and 55.2% of the patients answered greater than 80% of the text 218 
messages. 219 
 220 
Figure 2 illustrates the use of medications before the CATIs. Of the 2,246 CATIs reporting the use of 221 
FDCs by 564 patients, 29.9% reported an irregular use of FDCs (1 to 6 days). ICS use was reported by 222 





Single LABA use with or without concomitant ICS use was declared by 84 patients in 308 CATIs, and 224 
regular use (7-day use) was reported in 75.6% of their CATIs. SABA use was reported by 827 patients 225 
in 3696 CATIs: use was regular in 21.1% of the CATIs. 226 
 227 
FIGURE 2 228 
 229 
Occurrence of asthma exacerbation (AEx)  230 
During follow-up, 29.2% of patients experienced ≥1 AEx, with an average of 2.0 (±1.8) AEx events per 231 
patient. AEx events mostly consisted of new OCS courses (80% of AEx), often with unscheduled 232 
medical visits (72% of AEx). Few (3.3%) asthma-related hospital contacts were reported, and no 233 
asthma-related death occurred (Table 2). 234 
 235 
TABLE 2 236 
 237 
Risk of AEx during medication use 238 
No significantly increased risks of AEx were associated with patient-reported medication use over time 239 
when comparing periods of regular use with periods of nonuse of FDCs (0.98, 95% CI: 0.73-1.33) and 240 
single ICS (0.90, 95% CI: 0.61-1.33). By contrast, the risk of AEx non-significantly increased with 241 
regular use of single LABAs (1.29, 95% CI: 0.76-2.17), while increase was larger and significant with 242 
regular use of SABAs (2.09, 95% CI: 1.36-3.21). 243 
A greater number of AEx events occurred in French than in British patients (1.72, 95% CI: 1.06-2.81). 244 
Women had a significantly increased risk of AEx compared to men (1.39, 95% CI: 1.08-1.78), and 245 
children displayed a significantly increased risk compared to adults (1.40, 95% CI: 1.05-1.87). All three 246 





1.43) for pre-study OCS courses; (1.42, 95% CI: 1.07-1.88) for medium versus low initial dose and 248 
(1.52, 95% CI: 1.11-2.08) for high versus low ICS initial dose, and (1.49, 95% CI: 1.15-1.94) for use of 249 
LTARs at inclusion. (Table 3; Figure 3).  250 
 251 
TABLE 3 252 






Our prospective cohort followed 908 patients with persistent asthma in France and in the UK, including 255 
222 children, with 4,248 assessments of the actual use of therapy and occurrence of exacerbations. High 256 
proportions of patients did not make appropriate use of controller therapy, with 29.9% and 34.6% of 257 
CATIs revealing an irregular use of FDCs and ICS, respectively. By contrast, when patients used 258 
LABAs in single inhalers, they mostly used it regularly (75.6% of CATIs), and many patients declared 259 
a regular use of SABAs (21.1% of CATIs). Altogether, 29% of the patients experienced an exacerbation: 260 
when compared to periods of non-use, the risk decreased slightly, but not significantly so, under regular 261 
FDC and ICS use while it increased moderately -albeit not significantly- during regular use of single 262 
LABAs inhalers, and even more under regular use of SABAs, with a significant doubling of the risk. A 263 
significantly higher risk was observed in France than in the UK, in female patients, in children aged 6-264 
12 years compared to adults, and in patients with more severe asthma.  265 
 266 
For FDCs, our ‘real world’ results complement the findings of recent RCTs comparing the occurrence 267 
of serious adverse outcomes in patients treated with FDCs compared with ICS monotherapy, where 268 
FDCs and ICS were associated with similar rates of these outcomes 7, 8. Our data are consistent with a 269 
recent observational study conducted with claims data that reported a 20% decreased risk of asthma-270 
related hospitalization in patients treated with FDCs compared to LABAs and ICS in distinct inhalers 271 
14, highlighting the absence of risk when patients used LABAs concomitantly with ICS and not as a 272 
monotherapy, as advised by  guidelines 15, 16. Interestingly, in our study, FDCs and ICS were declared 273 
to be used irregularly in 30% and 35% of episodes of use, supporting observations of common 274 
inappropriate use of asthma controller therapy, and so contributing to the increased risk of exacerbations 275 
recorded in patients using short- or long-acting bronchodilators in single inhalers.9 SABA or LABA and 276 
ICS use in distinct inhalers may indeed become an at-risk treatment use when patients preferentially use 277 
their bronchodilator at the expense of ICS therapy 17. Although this pattern of use was not directly 278 
observed in our study, differential use between LABA and ICS has been documented by a study showing 279 
that 17.7% of patients receiving LABAs and ICS in distinct inhalers had episodes of treatment with 280 





19. Notably, in our study, patients reported irregular (1-6 days) use of ICS in 35% of declared episodes 282 
of use, supporting the assumption that LABAs -and SABAs- are occasionally used without simultaneous 283 
ICS therapy 9.  284 
For bronchodilators in single inhalers use, the data reveal that the majority of LABAs uses tended to be 285 
regular (>75%), and regular use increased the odds of exacerbations with 29%  compared to periods of 286 
non-use, in agreement with available evidence 20. However, the number of patients using single LABA 287 
inhalers decreases fastly, as shown by recent studies 21, precluding more robust findings from this study 288 
population. Nonetheless, the use of LABAs in monotherapy is contra-indicated in asthma, and the 289 
identification of patients still relying on this therapy suggests that additional efforts are needed to raise 290 
prescribers’ awareness of the risks related to this use. Less expected was the regular use of SABAs 291 
declared in 21% of the CATIs, while more than 80% of the patients used SABAs. This implies that 292 
many SABA users had periods of regular use, despite recommendations 13. This observation is likely 293 
related to the overall low level of control observed in the study population, with patients reporting a 294 
poor control of asthma in more than 50% of the interviews 22. Combined with the known irregularity of 295 
use of inhaled corticosteroids 23, this finding contributes to the increased risk of exacerbation in regular 296 
SABA users, a situation much more common than regular LABA use, as illustrated by our analysis of 297 
adherence data 22. This underlines the need of further emphasizing the appropriate use of SABAs 2, 3. 298 
 299 
The findings on the effects of socio-demographic characteristics and asthma severity on the risk of 300 
exacerbations are consistent with published evidence. First, women had an increased risk of 301 
exacerbations compared to men, as previously reported in relation to poorer asthma control and 302 
exacerbation occurrence 24. Second, more frequent exacerbations were observed in France than in the 303 
UK. This difference might in part be attributed to differences in health care systems and the management 304 
of asthma in the two countries. Also, exacerbations occurred more often in children than in adults, 305 
consistent with previous reports 25. Potential explanations include a higher prevalence of viral infections 306 
or better reporting of asthma outcomes by caregivers in this study. 26. Last, higher risks of exacerbation 307 





cotherapy with LTRAs-, which represents a validation of their use to control confounding effects due to 309 
asthma severity.  310 
 311 
Part of the results should be interpreted with some caution given the small sample of patients using 312 
LABAs in single inhalers, in contrast to the high prevalence of SABA use. Significant changes in LABA 313 
use in favor of FDCs at the expense of single LABA and ICS inhalers have indeed been observed 314 
recently. In France, a 2.4-fold decrease in the number of users of LABA monotherapies was identified 315 
between 2006 and 2016: from 4.1% to 1.7%21. In the UK, the prevalence of single LABA use also 316 
decreased sharply from 11.3% to 5.4% between 2007 and 2011 9. Moreover, frequent changes in asthma 317 
medication prescription and use were identified during the follow-up period in our study population. 318 
Therefore, to optimize data analysis, a GLM model was used, taking into account distinct periods of 319 
therapy in individual patients, to compare the occurrence of exacerbations between periods “at risk” -320 
periods where patients used medications with potential impact on exacerbations- and periods with no 321 
such use. Our findings that sorted exacerbations according to prior patterns of use of medications (none, 322 
irregular, regular) appropriately reflected routine care, and identified the real-world uses of therapy that 323 
put the patients at maximal risk of adverse outcome. The study thus provides information that 324 
complements studies focused on fatal and near-fatal outcomes, or on head-to-head comparisons between 325 
treatment strategies.  326 
Only 8.4% of the patients contacted in the UK agreed to participate. The enrollment process was 327 
however complex, as potential subjects had to be identified by the practice, before receiving information 328 
and providing specific agreements by mail. The selection bias did not affect the findings, as the study 329 
investigated the relationship between different patterns of use of therapy, and exacerbations. 330 
Furthermore, a parallel study conducted on another population of British patients showed similar data, 331 
with common overuse of SABAs and relative underuse of ICS 9, supporting the validity of our findings. 332 
The response rates to texting or the failure to accurately recall details may also have contributed to some 333 
irregularities in data acquisition, but this limitation affected all treatment groups in a similar way, and it 334 
was unlikely to impact the findings, as significant efforts were made to contact all patients regularly by 335 





studies that rely on telephone interviews without actually reviewing medical records or ordering specific 337 
tests always have some inherent weaknesses. 338 
Other potential limitations were the moderate severity of asthma in the study, as a result of the enrolment 339 
from primary care practices, and the age range (6-40) imposed by the need to prevent inclusion of 340 
COPD, as asthma may be difficult to distinguish from COPD in primary care.  These limitations possibly 341 
hampered the generalizability of our findings, but recent data confirm that asthmatic patients managed 342 
in primary care may experience major outcomes, supporting the clinical relevance of our findings 3. 343 
 344 
In conclusion, the study provides valid insights into the relationship between the use of short- and long-345 
acting bronchodilators and the occurrence of adverse outcomes in a real-world population of patients 346 
with asthma in two different countries. It is one of the few studies providing detailed and prospective 347 
patient-reported data on medication use and effects through close patient follow-up, allowing valid 348 
investigations of medication use and effects. 349 
The study also represented an opportunity to investigate asthma management in primary care settings in 350 
more depth in France and the UK from patient and health care professional perspectives 27, 28. The study 351 
supports the reassuring results obtained for LABA/ICS FDCs in recent randomized trials 7, 8. It also 352 
highlighted the low number of patients who are currently receiving single LABAs, notably in 353 
monotherapy, suggesting that recommendations have in part been implemented 1. However, the 354 
observed overuse of SABAs (more than 20% of SABA uses) is a major concern, which is also the case 355 
-despite limited and decreasing use-, for the extended use of LABAs in single inhalers, and both 356 
situations warrant educational efforts towards health care professionals and patients (self-management 357 
training). Others risk factors for exacerbations were identified such as severity, female gender, age, and 358 
country 28.  359 
In summary, the results corroborate findings from clinical trials on FDC safety, and support the validity 360 
of the recent GINA recommendations, advising against regular bronchodilator use, certainly in the 361 
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Table 1: Patients’ characteristics at inclusion (N=908) 435 
 436 
Characteristics N (%) 
Gender  
 Male 485 (53.4%) 
 Female 423 (46.6%) 
Age at inclusion 
 18-40 years 507 (55.8%) 
 12-17 years 179 (19.7%) 
 6-11 years 222 (24.5%) 
Country 
 United Kingdom 161 (17.7%) 
 France 747 (82.3%) 
Medications at inclusion 
 ICS without LABAs 262 (28.9%) 
 LABAs/ICS FDCs 536 (59.0%) 
 LABAs + ICS (distinct inhalers) 83 (9.1%) 
 LABAs in monotherapy (without ICS) 27 (3.0%) 
Prescribed daily dose of ICS at the initial CATI in µg (1) (2) 
 Low 411 (45.3%) 
 Medium 299 (32.9%) 
 High 198 (21.8%) 
Prescribed leukotriene receptor antagonists at the initial CATI (1)  
 No 710 (78.2%) 
 Yes 198 (21.8%) 
SABA use at the initial CATI 
 Daily or almost (‘regular’) 205 (22.6%) 





 Nonuse 139 (15.3%) 
 
Mean (SD) 
# of OCS courses during the pre-study period (1)(3) 0.45 (0.90) 
(1) Markers of asthma severity. (2) High: > 1,000 µg of the beclomethasone equivalent dose (>400 µg in children); medium: 437 
500 to 1,000 µg of the beclomethasone equivalent dose (200 to 400 µg in children); low: ≤500 µg of the beclomethasone 438 
equivalent dose (≤200 µg in children). (3) The pre-study period corresponds to the one-year selection period before inclusion. 439 
 440 














% of patients 
affected 




Any OCS course  212 23.3% 24.9% 
Any unscheduled medical visit 
for asthma 
190 20.9% 20.4% 
Any hospital contact 
(Emergency Room visit or 
hospital admission due to 
asthma) 
30 3.3% 2.6% 
Death due to asthma 0 0 0 
Any outcome (overall)  265 29.2% 30.6% 
(1) Percentages were not mutually exclusive, as patients could be prescribed an OCS course during a medical contact. 444 





Table 3: Risk of asthma exacerbations during follow-up in groups stratified according to medication use and patient 446 
characteristics (4,248 CATIs in 908 patients) 447 
 448 
Variable  Odds ratio 95% CIs p-value 
Lower Upper 
Single LABA use (1) (2) 
0 day . . . . 
1 to 6 days 0.45 0.11 1.93 0.29 
7 days 1.29 0.76 2.17 0.34 
LABA/ICS FDC use (2) 
0 day . . . . 
1 to 6 days 0.93 0.64 1.35 0.70 
7 days 0.98 0.73 1.33 0.91 
Single ICS use (2) 
0 day 































United Kingdom . . . . 
France 1.72 1.06 2.81 0.03 
Gender 
Male . . . . 
Female 1.39 1.08 1.78 0.01 
Age group 
18-40 years . . . . 
12-17 years 0.87 0.60 1.25 0.44 
6-11 years 1.40 1.05 1.87 0.02 
# of OCS courses during the pre-study period 1.29 1.16 1.43 <0.01 
Prescribed daily ICS dose 
(µg of the beclomethasone 
equivalent dose) at initial 
CATI (3) 
Low . . . . 
Medium 1.42 1.07 1.88 0.02 







(LTRAs) at initial CATI  
No . . . . 
Yes 1.49 1.15 1.94 0.01 
(1) LABAs were used with ICs in distinct inhalers or in monotherapy. 449 
(2) Time-varying measurements obtained at each CATI. 450 
(3) High: > 1,000 µg of the beclomethasone equivalent dose (>400 µg in children); medium: 500 to 1,000 µg of the 451 
beclomethasone equivalent dose (200 to 400 µg in children); low: ≤500 µg of the beclomethasone equivalent dose 452 
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